Summary
774.61
0.50
(0.06%)
09/16/2026
Regeneron Pharmaceuticals, Inc. (REGN)Performance
Historical returns1D
0.06%
1W
-4.15%
1M
-3.84%
3M
26.02%
6M
2.55%
1Y
35.89%
5Y
19.85%
Snapshot
Key statisticsClose
774.61
Change
0.50
Change %
0.06%
Open
775.82
Day Range
771.80 – 779.98
Volume
379,657
Avg Vol (20d)
606,780
Rel Vol
0.63x
52W Range
538.23 - 859.34
vs 52W High
-9.86%
vs 52W Low
43.92%
Gap
-10.11
Market Cap
USD 79.80B
Beta
0.39
Dividend Yield
0.48%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
8 bullish · 0 bearish pointsBullish view
- Beat consensus EPS in 7 of the last 8 quarters.
- The Q2 '26 quarter beat on EPS by $4.13 (40.6% above consensus).
- Revenue in the same quarter came in $473.45M ahead of consensus.
- Operating margin expanded to 33.1% in the Jun 2026 quarter from 29.4% a year earlier.
- Gross margin improved to 86.6% from 85.6% a year ago.
- Revenue grew 16.7% year on year in the Jun 2026 quarter to $4.29B.
- Holds 5.8% above its 200-day average.
- Has recovered 40.2% off the 52-week low of $552.67.
Bearish view
None of the valuation, growth and margin, earnings-execution, analyst or price-trend checks produced a bearish signal on current data.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returnsSep 16
2026
$774.61 0.06%Latest
Regeneron Pharmaceuticals rose 0.06% to $774.61, though on light volume (0.6× the 20-day average). The move left the stock 9.1% below its 52-week high.
Sep 15
2026
$774.11 2.47%
Regeneron Pharmaceuticals fell 2.47% to $774.11, its biggest one-day drop in 2 months. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.05% that session, leaving about 2.3 points of the move unexplained by the market after adjusting for a 0.39 beta. The move erased $2.10B of market value.
Sep 8
2026
$810.31 2.10%
Regeneron Pharmaceuticals fell 2.10% to $810.31. The move was broadly in line with its sector — the S&P 500 fell 0.55% while Healthcare peers (XLV) fell 2.52% the same session — so little of it was company-specific. Shares opened with a 1.61% gap down, lost their 20-day moving average and marked a 3rd consecutive decline. The move erased $1.86B of market value.
Sep 2
2026
$852.03 3.42%52W High
Regeneron Pharmaceuticals rose 3.42% to $852.03, its biggest one-day gain in 2 weeks and a 1.8σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 gained 0.44% while Healthcare peers (XLV) rose 0.75% that session, leaving about 2.7 points of the move unexplained by its sector. Shares closed near the session high (91% of the day's range), set a 52-week closing high and marked a 3rd consecutive advance. The move added $3.01B of market value.
Sep 1
2026
$823.82 3.10%
Regeneron Pharmaceuticals rose 3.10% to $823.82, a 1.7σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.69% while Healthcare peers (XLV) rose 0.66% that session, leaving about 2.4 points of the move unexplained by its sector. Shares opened with a 1.22% gap up, closed near the session high (96% of the day's range) and reclaimed their 20-day moving average. The move added $2.64B of market value.
Aug 19
2026
$840.84 3.78%52W High
Regeneron Pharmaceuticals rose 3.78% to $840.84, its biggest one-day gain in 3 weeks and a 2.1σ move against its 60-day volatility. The move was broadly in line with its sector — the S&P 500 gained 0.21% while Healthcare peers (XLV) rose 3.51% the same session — so little of it was company-specific. Shares opened with a 1.25% gap up, closed near the session high (86% of the day's range), set a 52-week closing high and marked a 3rd consecutive advance. The move added $3.27B of market value. Historically, after 2.1σ-or-larger up days, Regeneron Pharmaceuticals returned -0.64% on average over the following 5 sessions (47% positive, n=15).
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 769.80 +0.62% on 09/15/26 | 859.34 -9.86% on 09/03/26 | -30.38 (-3.77%) since 08/17/26 | |
| 3-Month | 594.20 +30.36% on 06/22/26 | 859.34 -9.86% on 09/03/26 | +160.60 (+26.16%) since 06/16/26 | |
| 6-Month | 590.82 +31.11% on 06/02/26 | 859.34 -9.86% on 09/03/26 | +17.59 (+2.32%) since 03/17/26 | |
| YTD | 590.82 +31.11% on 06/02/26 | 859.34 -9.86% on 09/03/26 | +1.30 (+0.17%) since 01/02/26 | |
| 52-Week | 538.23 +43.92% on 10/13/25 | 859.34 -9.86% on 09/03/26 | +204.95 (+35.98%) since 09/15/25 | |
| 5-Year | 473.33 +63.65% on 06/05/25 | 1,199.84 -35.44% on 08/27/24 | +111.70 (+16.85%) since 09/08/21 |
New Highs
Historical highs5-Day
1×
-2.41% from peak
1-Month
2×
-9.09% from peak
3-Month
19×
-9.09% from peak
6-Month
9×
-9.09% from peak
YTD
5×
-9.09% from peak
52-Week
19×
-9.09% from peak
2-Year
0×
-32.85% from peak
3-Year
40×
-34.93% from peak
5-Year
66×
-34.93% from peak
10-Year
92×
-34.93% from peak
Financial SnapshotFY 2025
Full financialsRevenue
USD 14.34B
+1.0% YoY
Net Income
USD 4.50B
+2.1% YoY
EPS
43.07
+5.3% YoY
Gross Margin
85.4%
Operating Margin
24.9%
Net Margin
31.4%
EBITDA
USD 5.82B
Free Cash Flow
USD 4.08B
28.4% margin
ROE
14.4%
ROA
11.1%
Debt / Equity
0.09x
net debt -USD 412.20M
Cash & Equiv.
USD 3.12B
News
All newsNovo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat...
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to...
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
[url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regene
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller
KlickAnalytics AI
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.earnings_moves(NVDA)
→ ka.options_expected_move(NVDA)
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with
“Screen the S&P 500 for oversold quality names.”
“Compare AAPL and MSFT over the last 5 years.”
“What moved the market today, and why?”
“Backtest a 50/200 crossover on TSLA.”
Create a free account to start asking
No credit card required. Confirm your email and the platform is open.
Create a free account
Sign in